U.S. Food and Drug Administration (FDA) · United States
FDA Food Labeling - Structure/Function Claims (21 CFR 101.93)
Dietary supplement structure/function claims must not be disease claims and must carry FDA's verbatim disclaimer on the label; the manufacturer must notify FDA and hold substantiation.
21 CFR 101.93; 21 U.S.C. 343(r)(6)
What is FDA Food Labeling - Structure/Function Claims (21 CFR 101.93)?
Dietary supplement structure/function claims must not be disease claims and must carry FDA's verbatim disclaimer on the label; the manufacturer must notify FDA and hold substantiation. Apply to dietary supplement labels, packaging and product pages that make structure/function claims. This guide summarizes the supplied rule information for marketing review. Use the linked official source to confirm the current text, applicability
Dietary supplement structure/function claims must not be disease claims and must carry FDA's verbatim disclaimer on the label; the manufacturer must notify FDA and hold substantiation.
How can marketing teams comply?
Apply to dietary supplement labels, packaging and product pages that make structure/function claims.
What is FDA Food Labeling - Structure/Function Claims (21 CFR 101.93)?
Dietary supplement structure/function claims must not be disease claims and must carry FDA's verbatim disclaimer on the label; the manufacturer must notify FDA and hold substantiation.
Supplements, cosmetics, foods and CBD products become unapproved drugs if their marketing claims to diagnose, treat, cure, mitigate or prevent disease, and cosmetics also may not claim to affect body structure or function.
OTC external drug products covered by 21 CFR 358 (warts, corns and calluses, ingrown toenails, lice, dandruff, seborrheic dermatitis, psoriasis) may only claim the uses and actives in their monograph.
Food and supplement labels may link a substance to reduced disease risk only through FDA-authorized or qualified health claims, in the required form, and only on foods meeting nutrient eligibility; disease treatment claims are not allowed.
Infant formula and baby food marketing must not be misleading, including claims of equivalence to breast milk, disease prevention, guaranteed development or absolute contaminant-free status; formulas must meet FDA nutrient and notification requirements.
Firm communications sharing scientific information on unapproved uses with HCPs must follow FDA's January 2025 final SIUU guidance: scientifically sound sources, required disclosures, no persuasive elements, and separation from promotion.
Prescription drug promotion must stay within the approved indication; information on unapproved uses may be shared only separately from promotion under FDA's safe-harbor guidance or in reply to unsolicited requests.
Request a free compliance scan of your homepage and book a time with Warrant.